Background:
Materials and LinksPresentations: |
The HCV Drug Resistance Advisory Group (HCV DRAG) is an outgrowth of a proposal from the 1st International Workshop on Hepatitis C: Resistance and New Compounds in October 2006.
Objectives:
The objective of the HCV DRAG is to bring together parties interested in and working in HCV drug resistance to continue discussions focused on issues pertinent to HCV drug/biologic development and resistance testing.
The goals are to produce consensus recommendations of appropriate methodology for HCV resistance testing for drug/biologic development and for clinical practice; and to provide scientific guidance to facilitate discussion between industry and regulatory agencies in areas of HCV drug resistance.
Status:
The third HCV DRAG meeting was on March 24, 2009.
The Planning Committee for this project includes:
Dale Kempf - AbbottAnn Kwong - Vertex
Veronica Miller - Forum for Collaborative HIV Research
Nathalie Morgensztejn -EMEAJules O'Rear - FDA
Neil Parkin - WHOJean-Michel Pawlotsky -Henri Mondor Hospital
Sponsors:
 |
 |
 |
|
 |
 |
|
 |
